FindTrial
Sign In

Physician's choice chemotherapy

DRUG6 trials

Sponsors

Pfizer, AstraZeneca, Zhejiang Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

BRCA 1 Gene MutationBRCA 2 Gene MutationBreast Cancer MetastaticBreast Cancer Stage IVLow-grade Serous Fallopian Tube CancerLow-grade Serous Ovarian CancerLow-grade Serous Peritoneal CancerMetastatic Breast Cancer

Phase 2

Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer
NCT02649101
Zhejiang Cancer HospitalMetastatic Breast Cancer
Start: 2015-10-31End: 2017-10-31Target: 60Updated: 2016-01-07
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
CompletedNCT04680988
Jiangsu HengRui Medicine Co., Ltd.Recurrent or Metastatic Cervical Cancer
Start: 2021-04-05End: 2025-07-07Updated: 2025-08-05

Phase 3

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
TerminatedNCT01849874
PfizerLow-grade Serous Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Low-grade Serous Peritoneal Cancer
Start: 2013-06-27End: 2022-08-23Updated: 2023-10-30
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
CompletedNCT02000622
AstraZenecaBRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer Metastatic
Start: 2014-03-27End: 2025-12-23Updated: 2026-02-13
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
NCT04296370
Jiangsu HengRui Medicine Co., Ltd.Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Start: 2020-07-13End: 2025-06-30Target: 474Updated: 2020-08-10
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
RecruitingNCT06889688
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer Stage IV, Triple -Negative Breast Cancer
Start: 2025-02-21End: 2029-06-01Target: 246Updated: 2026-04-23

Related Papers

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
2025-12-01
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
2023-12-1911 citations
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
2023-09-2911 citations
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clinical Cancer Research2023-08-1521 citations
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)
ESMO Open2023-05-011 citations
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
Journal of Clinical Oncology2022-06-0114 citations
Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
2021-08-317 citations
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).
Journal of Clinical Oncology2021-05-209 citations
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
2020-10-2738 citations
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
2020-05-2930 citations
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.
Journal of Clinical Oncology2020-05-203 citations
Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Cancer Research2020-02-1510 citations
Abstract P6-13-05: Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes
Cancer Research2020-02-151 citations
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
2019-09-0116 citations
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
2019-08-2254 citations
Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.
Journal of Clinical Oncology2019-05-209 citations
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
2019-04-01510 citations
LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation
Annals of Oncology2018-10-015 citations
Abstract CT038: OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA</i> mutation (g<i>BRCA</i>m)
Cancer Research2018-07-013 citations
Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline <i>BRCA</i> mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.
Journal of Clinical Oncology2018-05-2012 citations

11 more papers not shown